Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3437-3446

  Guiducci, Cristiana ^a   Vicari, Alain P ^b   Sangaletti, Sabina ^a   Trinchieri, Giorgio ^b   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE CCL16; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 10 ANTIBODY; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CELL ACTIVATION; CELL COUNT; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; COLON CARCINOMA; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IN VIVO STUDY; LYMPH NODE; MACROPHAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR NECROSIS; TUMOR REJECTION; TUMOR VOLUME;

EID: 17144398046     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4262     Document Type: Article

References (41)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
2. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
4. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002;44:143-61.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
6. Vicari AP CC, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002;12:33-42.
7. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002;2:175-84.
8. Guiducci C, Di Carlo E, Parenza M, et al. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004;172:4026-36.
9. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999;190:125-33.
10. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541-9.
11. Mattner F, Magram J, Ferrante J, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
12. Castigli E, Alt FW, Davidson L, et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci U S A 1994;91:12135-9.
13. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80.
14. Goldrosen MH, Formeister J, Holyoke ED. Semi-automated method for the enumeration of cytotoxicity results. J Immunol Methods 1976;11:367-9.
15. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
16. Pulaski BAaSOR. Mouse 4t1 breast tumor model. In: Coligan J. DM, Shevach E, Strober W, Kruisbeek A, editors. Current Protocols in Immunology. NJ: Wiley; 2000.
17. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730-5.
18. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93.
19. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
20. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004;4:432-44.
21. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
22. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
23. Giovarelli M, Cappello P, Forni G, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 2000;164:3200-6.
24. Cappello P, Caorsi C, Bosticardo M, et al. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leukoc Biol 2004;75:135-42.
25. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249-58.
26. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247-53.
27. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892-9.
28. Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004;172:5861-9.
29. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004;113:774-83.
30. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92.
31. Brozna JP. Shwartzman reaction. Semin Thromb Hemost 1990;16:326-32.
32. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-45.
33. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998;63:418-28.
34. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
35. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161:2094-8.
36. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 2000;191:541-50.
37. Wan Y, Lu L, Bramson JL, et al. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-γ-secreting, CD8(+) CTL in vivo. J Immunol 2001;167:5027-33.
38. Schulz O, Edwards AD, Schito M, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000;13:453-62.
39. Shoudai K, Hieshima K, Fukuda S, et al. Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC. Biochim Biophys Acta 1998;1396:273-7.
40. Youn BS, Zhang S, Broxmeyer HE, et al. Isolation and characterization of LMC, a novel lymphocyte and monocyte chemoattractant human CC chemokine, with myelosuppressive activity. Biochem Biophys Res Commun 1998;247:217-22.
41. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.